Alcyomics is a pre-clinical service provider using Skimune®, non-artificial human skin explants to predict adverse immune reactions of novel compounds. The Skimune® platform also assess the efficacy of monoclonal antibodies, immune inhibitors and safety of cellular therapies.
Altis Biosystems has developed a stem cell platform that recreates the human intestinal epithelium, using proliferative stem cells and terminally differentiated cells. These cells are sourced from transplant-grade intestine. It is a high-throughput format, ideal for drug screening.
AlveoliX is a Swiss-based organ-on-chip company. Our product is comprised of different hardware components and the easy-to-handle organ-on-chip consumable AX12. On the AX12 healthy and diseased biomodels can be created to study drug safety and efficacy and to answer fundamental research questions.
Aracari’s vascularized micro-organ and tumor models incorporate perfused human vasculature for the physiologic delivery of nutrients, drugs and immune cells to multiple tissue and tumor types. These powerful next-generation tools are advancing discovery in immuno-oncology and drug development.
AxoSim is a premier provider of neurological drug discovery platforms. The company’s proprietary BrainSim™ and NerveSim™ platforms provide accurate, predictive models of the peripheral and central nervous systems, delivering clinically-actionable human data early in the drug development process.
BrainXell is a CNS-focused supplier of iPSC-derived neurons, astrocytes, and microglia. Cells are made from control in-house lines and from customer-supplied disease lines. In addition, standardized and custom assays are available incorporating these cells.
CN Bio is a leading bioengineering company specializing in single and multi-organ microphysiological systems and innovative lab technologies. We aim to provide systems that generate clinically translatable data that can enhance the development of tomorrow’s medicines.
Curi’s suite of human iPSC-derived products and services enable scientists to build more mature and predictive human iPSC-derived tissues—with a focus on cardiac, musculoskeletal, and neuromuscular models—for the discovery, safety testing, and efficacy testing of new drugs in development.
Draper is an independent engineering innovation company. We re-imagine and engineer biomedical solutions that improve health outcomes and set a new pace and effectiveness for medical innovation for our pharma and healthcare partners. We are a leader in organ-on-chip and microphysiological systems.
Emulate develops a breadth of Organ-Chip models with a focus on recreating the microenvironment and mechanical forces cells experience in vivo. Hardware automating media flow and stretch, Bio-Kits including chips and qualified human cells, and a range of standard and custom services are available.
Hesperos is accelerating drug discovery by providing safety and efficacy testing services using its Human-on-a-Chip, microphysiological system. This breakthrough technology enables unprecedented preclinical insight bringing better therapies to patients faster without the need for animal testing.
ImmuONE is a product provider of immune cell models and a specialized service provider for chemical safety assessment (e.g. e-cigarettes, cosmetics, therapeutics). We offer advanced in-vitro products and offer innovative in-house testing services using state-of-the-art equipment and techniques.
InSphero is the pioneer of industrial-grade, 3D-microtissue-based assay solutions and scaffold-free 3D organ-on-a-chip technology. The company specializes in liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and immuno oncology.
KIYATEC’s clinically validated, predictive 3D ex vivo assays characterize response to I/O, targeted, and chemo therapies. Data from our proprietary platforms span most solid tumors including ovarian, GBM, breast, & rare. Our services cover all phases of preclinical development thru clinical trials.
Lena Biosciences offers Perfused Organ Panel MPS with a Blood Substitute hemoglobin analog that yields a log-fold increase in CYP450 activity in primary human hepatocytes to identify mitotoxic metabolites and DILI. Services focus on efficacy and toxicity in liver, brain, tumor, and blood models.
Mimetas develops high-throughput healthy and diseased organ-on-a-chip models in the OrganoPlate®, a screening-compatible microfluidics platform that supports the recreation of native tissue structures, and their interaction with compounds, signaling factors, disease triggers, and co-cultured cell types.
Nortis’ ParVivo™ technology simulates physiological fluidic flow mimicking in-vivo tissue conditions. The ParVivo™ pre-seeded chip platform provides chips with quality-controlled kidney, vascular or liver tissues. Our team of tissue engineers routinely helps users developing novel tissue models.
Obatala Sciences™ offers products and services for researchers working on diabetes, obesity, and cancer among other diseases. Obatala®’ products include the first human-derived hydrogel, ObaGel™, adipose-derived stem cells, and differentiation media, and the ObaCell Fat-on-a-Chip System™.
StemoniX de-risks drug discovery using human biology with proprietary human iPSC-derived 2D & 3D neural spheroids and organoids and advanced data analytics. We accelerate drug discovery through clinically translatable neurotoxicity testing, advanced disease modelling, and high-throughput screening.
Stem Pharm offers functional 2-D and 3-D human tissue models for disease modeling, drug discovery, and toxicity screening. We specialize in neural organoid and vascular models. Our team of scientists can also help users identify and develop unique synthetic hydrogels for their own MPS...Featured Article - 1Featured Article - 2Featured Article - 3
Organ-on-Chip models from SynVivo recreate complex microvasculature including scale, morphology, hemodynamic shear stress, and cellular interactions in a perfused microfluidic chip environment. Validated models include Air Liquid Interface for Lung, Blood-Brain Barrier, Tumor, DIVI, Inflammation.
TARA Biosystems harnesses innovations in stem cell biology and tissue engineering to generate in vitro cardiac biology that recapitulates human physiology with unprecedented fidelity, capturing integrated physiologic endpoints across a wide repertoire of cardiac disease phenotypes.